Triazine–Carbosilane Dendrimersomes Enhance Cellular Uptake and Phototoxic Activity of Rose Bengal in Basal Cell Skin Carcinoma Cells-Reference-Cited by-同舟云学术

Triazine–Carbosilane Dendrimersomes Enhance Cellular Uptake and Phototoxic Activity of Rose Bengal in Basal Cell Skin Carcinoma Cells

Published:2022-03 Issue: Volume:Volume 17 Page:1139-1154
ISSN:1178-2013
Container-title:International Journal of Nanomedicine
language:en
Short-container-title:IJN

Author:

Sztandera Krzysztof,Gorzkiewicz Michał^ORCID,Bątal Mateusz,Arkhipova Valeria,Knauer Nadezhda^ORCID,Sánchez-Nieves Javier^ORCID,de la Mata Fco Javier^ORCID,Gómez Rafael,Apartsin Evgeny^ORCID,Klajnert-Maculewicz Barbara^ORCID

Publisher

Informa UK Limited

Subject

Organic Chemistry,Drug Discovery,General Medicine,Biomaterials,Bioengineering,Biophysics,Pharmaceutical Science

Reference66 articles.

1. Update in the Management of Basal Cell Carcinoma

2. Targeted Therapy of Cancer Using Photodynamic Therapy in Combination with Multi-faceted Anti-Tumor Modalities

3. Phthalocyanine Derivatives Possessing 2-(Morpholin-4-yl)ethoxy Groups As Potential Agents for Photodynamic Therapy

4. Nanocarriers in photodynamic therapy—in vitro and in vivo studies

5. Recent Strategies to Develop Innovative Photosensitizers for Enhanced Photodynamic Therapy

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development of Novel β-Carboline/Furylmalononitrile Hybrids as Type I/II Photosensitizers with Chemo-Photodynamic Therapy and Minimal Toxicity;Molecular Pharmaceutics;2024-05-31

2. Oxygen-supplying ROS-responsive prodrug for synergistic chemotherapy and photodynamic therapy of colon cancer;Frontiers in Pharmacology;2024-02-14

3. Unveiling the potential of photodynamic therapy with nanocarriers as a compelling therapeutic approach for skin cancer treatment: current explorations and insights;RSC Advances;2024

4. Cellular uptake of rose bengal is mediated by OATP1B1/1B3 transporters;Bioelectrochemistry;2023-08

5. The Spicy Science of Dendrimers in the Realm of Cancer Nanomedicine: A Report from the COST Action CA17140 Nano2Clinic;Pharmaceutics;2023-07-24